---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-000247"
form_type: "8-K"
ticker: "ELUT"
cik: "0001708527"
company_name: "ELUTIA INC."
filed_at: "2024-01-12T23:59:59+00:00"
generated_at: "2026-06-06T23:58:34.835953+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Elutia amends Ligand royalty deal; min annual payment rises to $4.4M, $5M milestone waived

## Summary
- Minimum Annual Royalty increased from $2.75M to $4.4M for 2024 and each year thereafter through May 2027.
- Quarterly minimum payment raised from ~$0.7M to $1.1M; $3.0M lump-sum paid for 2023 Q1-Q3 (half due Jan 20, 2024, half by Apr 10, 2024).
- Ligand waived a $5.0M milestone payment that was due in Q2 2023; royalty rate remains 5% of sales on CanGaroo, ProxiCor, Tyke, VasCure.

## SEC filing metadata
- accession: 0001558370-24-000247
- form_type: 8-K
- ticker: ELUT
- cik: 0001708527
- company_name: ELUTIA INC.
- filed_at: 2024-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708527/000155837024000247/0001558370-24-000247-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708527/000155837024000247/elut-20240110x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-000247
- JSON: https://secwatch.observer/filing/0001558370-24-000247.json
- Plain text: https://secwatch.observer/filing/0001558370-24-000247.txt

## Key facts
- Material Agreements
  ELUTIA INC. amended Amendment No. 1 to Royalty Agreement with Ligand Pharmaceuticals Incorporated (effective 2024-01-10).
  - Action: amendment
  - Counterparty: Ligand Pharmaceuticals Incorporated
  - Effective: 2024-01-10
  source text: On January 10, 2024, Elutia Inc. (the “Company”), through its subsidiary Elutia Med LLC, a Delaware limited liability company (formerly known as Aziyo Med, LLC) (“Elutia Med”), entered into that certain Amendment No. 1 to Royalty Agreement (the “Amendment”), with Ligand Pharmaceuticals Incorporated, a Delaware corporation (“Ligand”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708527/000155837024000247/0001558370-24-000247-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.